JP4672021B2 - 標的ｍＲＮＡと相補的な塩基配列を有するｓｉＲＮＡを用いて標的ｍＲＮＡの発現を抑制する方法 - Google Patents

標的ｍＲＮＡと相補的な塩基配列を有するｓｉＲＮＡを用いて標的ｍＲＮＡの発現を抑制する方法 Download PDF

Info

Publication number
JP4672021B2
JP4672021B2 JP2007545384A JP2007545384A JP4672021B2 JP 4672021 B2 JP4672021 B2 JP 4672021B2 JP 2007545384 A JP2007545384 A JP 2007545384A JP 2007545384 A JP2007545384 A JP 2007545384A JP 4672021 B2 JP4672021 B2 JP 4672021B2
Authority
JP
Japan
Prior art keywords
binding energy
factor
points
value
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007545384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522613A5 (enExample
JP2008522613A (ja
Inventor
ヨング−チュル チョイ
ハン オー パク
ソリミ チョング
ヨング ジョー キム
サング ソー キム
セオン−ミン パク
サン−チョル キム
ギュマン ヨーン
キョング オーク チョイ
ヒョ ジン カン
Original Assignee
バイオニア コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオニア コーポレイション filed Critical バイオニア コーポレイション
Publication of JP2008522613A publication Critical patent/JP2008522613A/ja
Publication of JP2008522613A5 publication Critical patent/JP2008522613A5/ja
Application granted granted Critical
Publication of JP4672021B2 publication Critical patent/JP4672021B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007545384A 2004-12-08 2005-12-08 標的ｍＲＮＡと相補的な塩基配列を有するｓｉＲＮＡを用いて標的ｍＲＮＡの発現を抑制する方法 Expired - Fee Related JP4672021B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040103283 2004-12-08
PCT/KR2005/004207 WO2006062369A1 (en) 2004-12-08 2005-12-08 Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna

Publications (3)

Publication Number Publication Date
JP2008522613A JP2008522613A (ja) 2008-07-03
JP2008522613A5 JP2008522613A5 (enExample) 2011-01-13
JP4672021B2 true JP4672021B2 (ja) 2011-04-20

Family

ID=36578152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545384A Expired - Fee Related JP4672021B2 (ja) 2004-12-08 2005-12-08 標的ｍＲＮＡと相補的な塩基配列を有するｓｉＲＮＡを用いて標的ｍＲＮＡの発現を抑制する方法

Country Status (6)

Country Link
US (1) US20090155904A1 (enExample)
EP (1) EP1828415A4 (enExample)
JP (1) JP4672021B2 (enExample)
KR (1) KR101007346B1 (enExample)
CN (1) CN101120099B (enExample)
WO (1) WO2006062369A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
CN105176999A (zh) * 2015-08-13 2015-12-23 吉林大学 抑制survivin基因表达的双链siRNA、其应用及包含其的表达质粒及传递体
CN105063048A (zh) * 2015-08-13 2015-11-18 吉林大学 一种抑制Survivin基因表达的siRNA及其应用
CN112951322B (zh) * 2021-03-08 2023-09-26 深圳市新合生物医疗科技有限公司 一种基于网格搜索的规则权重分配siRNA设计方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1427008A (zh) * 2001-12-14 2003-07-02 殷冬生 设计与选择天然的siRNA作为基因药物的方法及药物配方
US20040002083A1 (en) * 2002-01-29 2004-01-01 Ye Ding Statistical algorithms for folding and target accessibility prediction and design of nucleic acids
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53

Also Published As

Publication number Publication date
WO2006062369A1 (en) 2006-06-15
US20090155904A1 (en) 2009-06-18
EP1828415A4 (en) 2009-07-01
KR20070094601A (ko) 2007-09-20
EP1828415A1 (en) 2007-09-05
CN101120099A (zh) 2008-02-06
JP2008522613A (ja) 2008-07-03
KR101007346B1 (ko) 2011-01-13
CN101120099B (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
Shabalina et al. Computational models with thermodynamic and composition features improve siRNA design
CN1926551B (zh) 用于基因沉默的siRNA的设计方法
Chalk et al. Improved and automated prediction of effective siRNA
SaeTrom et al. Weighted sequence motifs as an improved seeding step in microRNA target prediction algorithms
Ichihara et al. Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities
Vert et al. An accurate and interpretable model for siRNA efficacy prediction
Iribe et al. Chemical modification of the siRNA seed region suppresses off-target effects by steric hindrance to base-pairing with targets
CA2545675A1 (en) Rnai potency prediction method
Ding et al. Clustering of RNA secondary structures with application to messenger RNAs
Gong et al. Integrated siRNA design based on surveying of features associated with high RNAi effectiveness
Li et al. Predicting siRNA efficiency.
JP4672021B2 (ja) 標的ｍＲＮＡと相補的な塩基配列を有するｓｉＲＮＡを用いて標的ｍＲＮＡの発現を抑制する方法
Pascut et al. Silencing efficacy prediction: a retrospective study on target mRNA features
Ayyagari Design of siRNA molecules for silencing of membrane glycoprotein, nucleocapsid phosphoprotein, and surface glycoprotein genes of SARS-CoV2
EP1628993A2 (en) Methods and compositions for rna interference
Khan et al. Crafting a blueprint for MicroRNA in cardiovascular diseases (CVDs)
Pan et al. siPRED: predicting siRNA efficacy using various characteristic methods
Grinev et al. Prediction of gene expression regulation by human microRNAs in Plasmodium falciparum
Chaudhary et al. Development of a software tool and criteria evaluation for efficient design of small interfering RNA
WO2009042115A2 (en) Methods of designing short hairpin rnas (shrnas) for gene silencing
Gupta et al. A novel algorithm to design an efficient siRNA by combining the pre proposed rules of siRNA designing
Quillet et al. Prediction tools for miRNA targets: toward a better comprehension for Biologists
Ayllón Gavilán Off-Target Effects integration in Machine Learning Models for siRNAs 1 Prediction: Current Practices and Limitations
KR20070118764A (ko) 선택적 스플라이싱을 고려한 ｓｉＲＮＡ를 이용하여 표적ｍＲＮＡ의 발현을 억제하는 방법
Li et al. Genetic studies of diseases: Predicting siRNA efficiency

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101119

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101221

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110118

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140128

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees